During a live event, Karen Seiter, MD, discussed the role of the JAK/STAT pathway in myeloproliferative neoplasms and the use ...

Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives,” published in the ...

Panelists discuss how managing advanced polycythemia vera requires tailored approaches beyond hydroxyurea when patients show resistance (persistent hematocrit >45%, elevated white blood cell counts, ...

Join Drs Tania Jain and Prithviraj Bose as they discuss the available JAK inhibitors and how they use them to treat ...

MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual ...

Now, let’s shift our focus to AD. and the emerging role of immune modulators in the treatment of AD. Please discuss the findings presented at AAD 2025 regarding the association of ruxolitinib ...

Though not yet approved, investors are already eyeing the drug as a potential blockbuster. Its commercial rights holder in ...

Today, the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision in Incyte Corp. v. Sun ...

Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD ...

This week, we take a closer look at two precedential cases concerning pharmaceutical patent protections as applied to drugs in development.